The Mounjaro weight-loss jab is now available from GPs the NHS, but only for a limited group of patients with a BMI over 35 ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

The Health Secretary will set out a 10-year plan including proposals to bring down the cost of drugs such as Wegovy and ...

UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.